PortfoliosLab logoPortfoliosLab logo
TMDX vs. LUMN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TMDX vs. LUMN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TransMedics Group, Inc. (TMDX) and Lumen Technologies, Inc. (LUMN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TMDX achieves a -40.07% return, which is significantly lower than LUMN's 9.27% return.


TMDX

1D
-0.92%
1M
15.36%
YTD
-40.07%
6M
-42.50%
1Y
-48.97%
3Y*
-4.58%
5Y*
20.83%
10Y*

LUMN

1D
0.00%
1M
-15.52%
YTD
9.27%
6M
-0.12%
1Y
110.15%
3Y*
58.55%
5Y*
-8.90%
10Y*
-5.46%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TMDX vs. LUMN - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
TMDX
TransMedics Group, Inc.
-40.07%95.11%-21.01%27.88%222.13%-3.72%4.68%-6.12%
LUMN
Lumen Technologies, Inc.
9.27%46.33%190.16%-64.94%-55.48%38.82%-19.18%23.83%

Correlation

The correlation between TMDX and LUMN is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.22

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.22

Correlation (All Time)
Calculated using the full available price history since May 2, 2019

0.22

Fundamentals

Market Cap

TMDX:

$2.64B

LUMN:

$8.48B

EPS

TMDX:

$4.34

LUMN:

-$1.75

PS Ratio

TMDX:

4.54

LUMN:

0.70

PB Ratio

TMDX:

5.34

LUMN:

0.73

Total Revenue (TTM)

TMDX:

$635.89M

LUMN:

$12.12B

Gross Profit (TTM)

TMDX:

$375.74M

LUMN:

$1.52B

EBITDA (TTM)

TMDX:

$125.51M

LUMN:

$1.12B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TMDX vs. LUMN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TMDX
TMDX Risk / Return Rank: 88
Overall Rank
TMDX Sharpe Ratio Rank: 99
Sharpe Ratio Rank
TMDX Sortino Ratio Rank: 1010
Sortino Ratio Rank
TMDX Omega Ratio Rank: 1111
Omega Ratio Rank
TMDX Calmar Ratio Rank: 1010
Calmar Ratio Rank
TMDX Martin Ratio Rank: 11
Martin Ratio Rank

LUMN
LUMN Risk / Return Rank: 7777
Overall Rank
LUMN Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
LUMN Sortino Ratio Rank: 7878
Sortino Ratio Rank
LUMN Omega Ratio Rank: 7777
Omega Ratio Rank
LUMN Calmar Ratio Rank: 7878
Calmar Ratio Rank
LUMN Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TMDX vs. LUMN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for TransMedics Group, Inc. (TMDX) and Lumen Technologies, Inc. (LUMN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TMDXLUMNDifference
Sharpe ratioReturn per unit of total volatility

-2.13

Sortino ratioReturn per unit of downside risk

-3.20

Omega ratioGain probability vs. loss probability

0.86

1.26

-0.40

Calmar ratioReturn relative to maximum drawdown

-0.84

2.17

-3.01

Martin ratioReturn relative to average drawdown

-1.99

4.11

-6.10

TMDX vs. LUMN - Sharpe Ratio Comparison

The current TMDX Sharpe Ratio is -0.85, which is lower than the LUMN Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of TMDX and LUMN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TMDX vs. LUMN - Drawdown Comparison

The maximum TMDX drawdown since its inception was -73.69%, smaller than the maximum LUMN drawdown of -95.26%. Use the drawdown chart below to compare losses from any high point for TMDX and LUMN.


Loading charts...

Drawdown Indicators


TMDXLUMNDifference

Max Drawdown

Largest peak-to-trough decline

-73.69%

-95.26%

+21.57%

Max Drawdown (1Y)

Largest decline over 1 year

-58.76%

-47.34%

-11.42%

Max Drawdown (3Y)

Largest decline over 3 years

-67.79%

-69.66%

+1.87%

Max Drawdown (5Y)

Largest decline over 5 years

-67.79%

-92.54%

+24.75%

Max Drawdown (10Y)

Largest decline over 10 years

-94.44%

Current Drawdown

Current decline from peak

-58.60%

-58.92%

+0.32%

Average Drawdown

Average peak-to-trough decline

-31.89%

-27.66%

-4.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.65%

24.94%

-0.29%

Volatility

TMDX vs. LUMN - Volatility Comparison

The current volatility for TransMedics Group, Inc. (TMDX) is 12.66%, while Lumen Technologies, Inc. (LUMN) has a volatility of 22.04%. This indicates that TMDX experiences smaller price fluctuations and is considered to be less risky than LUMN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TMDXLUMNDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.66%

22.04%

-9.38%

Volatility (6M)

Calculated over the trailing 6-month period

43.87%

57.12%

-13.25%

Volatility (1Y)

Calculated over the trailing 1-year period

58.06%

80.17%

-22.11%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

72.00%

85.30%

-13.30%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

71.72%

67.61%

+4.11%

Dividends

TMDX vs. LUMN - Dividend Comparison

Neither TMDX nor LUMN has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
LUMN
Lumen Technologies, Inc.
0.00%0.00%0.00%0.00%14.37%7.97%10.26%7.57%14.26%12.95%9.08%8.59%
TMDX
TransMedics Group, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

TMDX vs. LUMN - Financials Comparison

This section allows you to compare key financial metrics between TransMedics Group, Inc. and Lumen Technologies, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B20222023202420252026
173.93M
2.90B
(TMDX) Total Revenue
(LUMN) Total Revenue
Values in USD except per share items

TMDX vs. LUMN - Profitability Comparison

The chart below illustrates the profitability comparison between TransMedics Group, Inc. and Lumen Technologies, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-40.0%-20.0%0.0%20.0%40.0%60.0%80.0%20222023202420252026
58.2%
0
Portfolio components
TMDX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, TransMedics Group, Inc. reported a gross profit of 101.16M and revenue of 173.93M. Therefore, the gross margin over that period was 58.2%.

LUMN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lumen Technologies, Inc. reported a gross profit of 0.00 and revenue of 2.90B. Therefore, the gross margin over that period was 0.0%.

TMDX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, TransMedics Group, Inc. reported an operating income of 13.30M and revenue of 173.93M, resulting in an operating margin of 7.6%.

LUMN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lumen Technologies, Inc. reported an operating income of 602.00M and revenue of 2.90B, resulting in an operating margin of 20.8%.

TMDX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, TransMedics Group, Inc. reported a net income of 7.32M and revenue of 173.93M, resulting in a net margin of 4.2%.

LUMN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lumen Technologies, Inc. reported a net income of -200.00M and revenue of 2.90B, resulting in a net margin of -6.9%.


Frequently Asked Questions


TMDX and LUMN have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

LUMN has higher volatility (22.04%) compared to TMDX (12.66%). In terms of maximum drawdown, TMDX dropped -73.69% vs LUMN's -95.26%.

LUMN currently has the higher Sharpe Ratio (1.28 vs -0.85), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TMDX and LUMN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer